Most retatrutide coverage this year has been a numbers race: 28.3% average body weight loss at 12mg in TRIUMPH-1, 45.3% of participants dropping at least 30% of their body weight. But the most interesting retatrutide results of 2026 may not be the ones on the scales at all. Buried inside TRIUMPH-1 was a nested "basket" trial in people with moderate-to-severe obstructive sleep apnoea — and the effect size there is arguably the strongest signal yet that a triple agonist is being built to treat obesity's complications, not just obesity's weight.

Here's what was actually reported, what it means, and what it doesn't prove yet.

Retatrutide results in sleep apnoea: what TRIUMPH-1 reported

Eli Lilly's June 2026 release and its ADA presentation described a nested obstructive sleep apnoea (OSA) sub-study within TRIUMPH-1. In participants with moderate-to-severe OSA, retatrutide reduced the apnoea-hypopnoea index (AHI) by up to 36.1 events per hour — a 60.6% reduction — from a baseline of 58.6 events per hour at 80 weeks. (The trial literature uses the US spelling "apnea-hypopnea index"; we've used AHI throughout.)

Some context on that baseline: 58.6 events per hour is not borderline. An AHI above 30 is already classified as severe. This was a cohort deep in the severe range, and the average participant came out the other side with roughly 22 events per hour remaining — still abnormal, but a different clinical conversation entirely.

The same programme reported knee osteoarthritis pain reductions of up to 4.3 points (73.1%) in its other nested basket, and 65.3% of 12mg participants no longer met the BMI criterion for obesity.

Two caveats worth stating plainly. First, these figures come from company announcements and conference presentations — the full peer-reviewed publications of the TRIUMPH-1 baskets are the document that matters, and they are still working through the journals. Second, "up to" is doing work in every one of these numbers: it refers to the best-performing dose arm, not the average across all doses.

Why the basket design is the real story

The TRIUMPH programme's design was published in Diabetes, Obesity and Metabolism before the readouts landed, and it explains the strategy. Rather than running separate standalone trials for obesity, sleep apnoea and knee osteoarthritis, Lilly nested complication-specific baskets inside the main obesity trials, each with its own primary endpoint (AHI for OSA, pain scores for knee OA).

That is a regulatory play as much as a scientific one. Complication-specific endpoints are what unlock complication-specific label language — and label language is what payers and reimbursement committees read. It is the same logic that turned tirzepatide's sleep apnoea trial into a separate indication rather than a footnote.

For a drug that will inevitably be asked "why should the health system pay for this?", having hard endpoints in apnoea, joint pain, HbA1c and cardiovascular-risk populations is the answer being assembled in advance. You can read more about the wider programme on our clinical trials page.

The rest of the 2026 data package

The OSA finding doesn't sit alone. In July 2026, Lilly reported topline results from two more phase 3 trials: TRIUMPH-2 in adults with type 2 diabetes (1,152 participants; up to 20.8% weight loss and up to 1.6 percentage points of HbA1c reduction at 80 weeks) and TRIUMPH-3 in adults with obesity and established cardiovascular disease (1,949 participants; up to 22.6% weight loss at 80 weeks, with improvements in triglycerides, blood pressure and inflammatory markers).

Note the pattern in those numbers. Weight loss is consistently lower in the diabetes and cardiovascular cohorts than the 28.3% headline from TRIUMPH-1's general obesity population — which is exactly what has been observed with earlier incretin drugs, and a useful corrective to the idea that everyone gets the headline figure. Separately, TRANSCEND-T2D-1 reported HbA1c reductions of up to 2.0%.

With all four core TRIUMPH registrational trials now reported, CEO David Ricks told investors at the Q2 2026 earnings update that Lilly has the "complete clinical data package in hand", with a biologics licence application to the FDA planned for the first quarter of 2027. On the supply side, Lilly's US$3.5 billion Lehigh Valley plant in Pennsylvania — announced in January 2026 and slated to make retatrutide — isn't due to be operational until 2031, a reminder that manufacturing capacity, not data, may end up being the rate-limiting step.

What this means for Australia

Retatrutide is investigational everywhere, including here: it is not TGA-approved, and Eli Lilly has signalled regulatory filings from 2027, with Australia typically following the US and EU rather than leading. Nothing in the sleep apnoea data changes that timeline.

The reason the OSA result still matters locally is that untreated moderate-to-severe sleep apnoea is common in Australia's overweight and obese population — around 66.8% of Australian adults are overweight or obese — and CPAP is currently the mainstay, with well-known adherence problems. If a weekly injection eventually carries an apnoea indication, that reshapes what a sleep physician can offer. But "eventually" is the operative word, and any Australian access pathway will run through the TGA first. More detail on where things stand locally is on our Australia page.

Join the free updates list and we'll email you when the peer-reviewed TRIUMPH publications land and when regulatory filings are confirmed.

FAQ

What are the latest retatrutide results?

As of August 2026, all four core TRIUMPH phase 3 trials have reported topline results: up to 28.3% weight loss in TRIUMPH-1 (general obesity), up to 20.8% in TRIUMPH-2 (type 2 diabetes), up to 22.6% in TRIUMPH-3 (established cardiovascular disease) and 28.7% in TRIUMPH-4 (obesity with knee osteoarthritis). Nested sub-studies also reported sleep apnoea and joint pain outcomes.

Does retatrutide help with sleep apnoea?

In TRIUMPH-1's nested sleep apnoea basket, retatrutide reduced the apnoea-hypopnoea index by up to 36.1 events per hour (60.6%) from a severe baseline of 58.6 events per hour at 80 weeks. These are company-reported and conference-presented results, and retatrutide is not approved for sleep apnoea in any country.

When will retatrutide be approved?

Eli Lilly has said it plans to submit a biologics licence application to the US FDA in the first quarter of 2027. Approval decisions typically take around a year after filing, and Australian TGA registration would follow separately — so 2028 or later is the realistic window here.

Is retatrutide better than Ozempic or Mounjaro?

Retatrutide targets three receptors (GLP-1, GIP and glucagon) versus one for semaglutide (Ozempic/Wegovy) and two for tirzepatide (Mounjaro/Zepbound), and its phase 3 weight-loss numbers are higher than published figures for both. However, there is no completed head-to-head trial against tirzepatide, so cross-trial comparisons should be treated cautiously. See our comparison and safety notes.

Sources

Disclaimer: retatrutide.net.au is an independent information resource and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. This article is general information only and is not medical advice. Always speak with your GP or a qualified health professional about your own circumstances. Learn more about what retatrutide is.